ArticleBBA clinical2016
Urinary myeloid IgA Fc alpha receptor (CD89) and transglutaminase-2 as new biomarkers for active IgA nephropathy and henoch-Schönlein purpura nephritis.
Article in BBA clinical, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- New prognostic markers for IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 2026Review
- Modern biomarkers in IgA vasculitis with nephritis in children.Central-European journal of immunology · 2025Review
- IgA nephropathy.Nature reviews. Disease primers · 2023Review
- Present and Future of IgA Nephropathy and Membranous Nephropathy Immune Monitoring: Insights from Molecular Studies.International journal of molecular sciences · 2023Review
- IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- An Emerging Role for Neutrophil Extracellular Traps in IgA Vasculitis: A Mini-Review.Frontiers in immunology · 2022Review
- Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- IgA Vasculitis and IgA Nephropathy: Same Disease?Journal of clinical medicine · 2021Review
- The Involvement of Neutrophil Extracellular Traps in Disease Activity Associated With IgA Vasculitis.Frontiers in immunology · 2021Article
- Identification of differentially expressed circulating exosomal lncRNAs in IgA nephropathy patients.BMC immunology · 2020Article
- Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.Frontiers in immunology · 2020Review
- Serum Soluble CD89-IgA Complexes Are Elevated in IgA Nephropathy without Immunosuppressant History.Disease markers · 2020Article
- IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.Frontiers in immunology · 2019Review
- Article
- Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Clinical and experimental immunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN) are glomerular diseases that share a common and central pathogenic mechanism. The formation of immune complexes containing IgA1, myeloid IgA Fc alpha receptor (FcαRI/CD89) and transglutaminase-2 (TG2) is observed in both conditions. Therefore, urinary CD89 and TG2 could be potential biomarkers to identify active IgAN/HSPN.
methodsIn this multicenter study, 160 patients with IgAN or HSPN were enrolled. Urinary concentrations of CD89 and TG2, as well as some other biochemical parameters, were measured.
resultsUrinary CD89 and TG2 were lower in patients with active IgAN/HSPN compared to IgAN/HSPN patients in complete remission (P < 0.001). The CD89xTG2 formula had a high ability to discriminate active from inactive IgAN/HSPN in both situations: CD89xTG2/proteinuria ratio (AUC: 0.84, P < 0.001, sensitivity: 76%, specificity: 74%) and CD89xTG2/urinary creatinine ratio (AUC: 0.82, P < 0.001, sensitivity: 75%, specificity: 74%). Significant correlations between urinary CD89 and TG2 (r = 0.711, P < 0.001), proteinuria and urinary CD89 (r = - 0.585, P < 0.001), and proteinuria and urinary TG2 (r = - 0.620, P < 0.001) were observed.
conclusionsDetermination of CD89 and TG2 in urine samples can be useful to identify patients with active IgAN/HSPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.